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Review Article
Pediatric Statin Administration:
Navigating a Frontier with Limited Data
Jonathan Wagner, DO1-3 and Susan M. Abdel-Rahman, PharmD2,3
1
Ward Family Heart Center and 2Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation,
Children’s Mercy Hospital, Kansas City, Missouri; 3Department of Pediatrics, University of Missouri-Kansas City
School of Medicine, Kansas City, Missouri

Increasingly, children and adolescents with dyslipidemia qualify for pharmacologic intervention. As they
are for adults, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are the mainstay of
pediatric dyslipidemia treatment when lifestyle modifications have failed. Despite the overall success of
these drugs, the magnitude of variability in dose-exposure-response profiles contributes to adverse events
and treatment failure. In children, the cause of treatment failures remains unclear. This review describes the
updated guidelines for screening and management of pediatric dyslipidemia and statin disposition pathway to assist the provider in recognizing scenarios where alterations in dosage may be warranted to meet
patients’ specific needs.
INDEX TERMS atorvastatin, dyslipidemia, fluvastatin, lovastatin, pediatrics, pharmacogenomics, pharmacokinetics, pravastatin, rosuvastatin, simvastatin, statin
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INTRODUCTION
Cardiovascular disease remains the number
one cause of mortality in the United States.1
Despite significant advances in medical and surgical management for heart disease and stroke,
the burden of cardiovascular disease remains
alarming. Coronary artery disease (CAD) alone
accounts for 1 of every 7 deaths in the United
States.1 Although CAD has historically been perceived as a disease of middle to late adulthood,
data now support onset at a much younger age.
Clinically silent precursors to CAD, fatty streaks,
have been observed in children as young as 3
years of age with coronary involvement identified at adolescence.2 By the time individuals
reach their 20s studies suggest that the incidence
of coronary atherosclerosis can range from 45%
to 75%.3,4 Importantly, several studies confirm
that the risk factors observed in adults (e.g.,
elevated low-density lipoprotein [LDL], obesity,
hypertension, tobacco exposure, and diabetes)
also contribute to atherosclerosis in children.5,6
Collectively, these studies have illuminated the
380

need for preventive cardiovascular services in
children and young adults.
Trends in circulating lipid profiles support a role
for screening in children as part of preventative
care. The prevalence of total plasma cholesterol
(TC) concentrations in excess of 200 mg/dL has
risen to 10% in adolescents,7,8 a far cry from the
estimated 0.2% of the population that can attribute
this laboratory finding to familial hypercholesterolemia.9,10 This may be explained, in part, by the
rate of overweight/obesity in children, which as
in adults, can be associated with elevated cholesterol levels.11 Importantly, most adolescents with
elevated TC will continue to have elevated TC
into adulthood, and those who are overweight
have a 2-fold higher relative risk of CAD mortality,
independent of adult weight.12,13 When pediatric
weight and lipid profiles are considered together,
the prevalence of symptomatic CAD in young to
middle-aged adults is expected to increase by 5%
to 16% over the next 2 decades.14 This will likely
contribute to an additional 100,000 cases of early
coronary heart disease that are specifically due to
childhood obesity.
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org
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SCREENING AND MANAGEMENT
GUIDELINES
Since the last comprehensive review of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMGCoA) reductase inhibitors (statins) by Eiland et
al,15 the pediatric screening and management
guidelines have changed, prompting this update
for pediatric providers who make recommendations related to prescribing statins.
In 1992, the National Cholesterol Education
Program (NCEP) began recommending targeted
lipid screening in pediatric patients with risk factors for premature atherosclerotic cardiovascular
disease.16 This strategy exposed numerous cases
of asymptomatic dyslipidemia that previously
would have been neglected for decades. However, additional evidence suggests that simply
relying on family history alone will miss at least
30% of pediatric patients with moderate dyslipidemia.17 These previous NCEP guidelines also
focused on LDL screening, essentially ignoring
the combined dyslipidemic patterns that are observed in obese pediatric patients (i.e., increased
triglycerides, increased LDL, decreased highdensity lipoprotein [HDL]).
Realizing that a large proportion of at-risk
children would remain unidentified, the National
Heart, Lung, and Blood Institute convened an
expert panel on Cardiovascular Health and Risk
Reduction in Children and Adolescents to update
the pediatric preventive cardiovascular guidelines, including modifications to lipid screening
and management in childhood and adolescence.18
The most striking modification in the updated
NCEP guidelines resides in the domain on lipid
screening where the panel now recommends
universal lipid screening for all children between
the ages 9 and 11 years and again between 17
and 21 years of age.18 These age groups were
targeted specifically to screen patients prior to
and after puberty, when it is observed that TC
and LDL can fluctuate with growth and sexual
maturity.19,20 The updated guidelines also suggest
that lipid profiles can be obtained in either the
fasting or non-fasting state given the reliability
with either method.21 This offers the benefit of
facilitating screening in busy clinic settings where
non-fasting lipid profiles may be easier to obtain.
Treatment guidelines were also clarified in the
new guidelines with the goal of minimizing the
burden of CAD in young adults. As expected,
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org

Table 1. Treatment Cutpoints for Statin Therapy*
LDL

Presence of Concurrent Factors

≥190 mg/dL

None

160-189 mg/dL

Positive family history of early
CVD
or
1 high-level RF for early CVD
or
2 moderate-level RF for early CVD

130-159 mg/dL

2 high-level RF for early CVD
or
1 high-level and 2 moderate-level
RF for early CVD

CVD, cardiovascular disease; LDL, low-density lipoprotein; RF, risk
factor
* Decisions regarding pharmacologic treatment of dyslipidemia
were based on the average results of 2 lipid profiles obtained at
least 2 weeks apart but no more than 3 months apart.

diet and exercise are the first steps in which a provider managing children with lipid abnormalities should implement a change. When lifestyle
modifications fail to improve lipid profiles over
a 6-month period, pharmacologic therapy may
be warranted to reverse lipid abnormalities. In
children older than 10 years of age, use of pharmacologic management should be based on the
average results of 2 lipid profiles obtained at least
2 weeks apart but no more than 3 months apart.
The thresholds used to determine when drug
therapy should be initiated are mirrored from the
1992 NCEP guidelines outlined in Table 1. The
treatment algorithm is based on a combination of
LDL level, family history, and/or associated risk
factors and/or risk conditions (Table 2).
Contrasted with the adult guidelines which
establish a threshold for treatment at ≥190 mg/
dL, the implications of expanded drug use in
children below this threshold are self-evident. A
recent publication quantified this impact in just
the adolescent population (17-21 years of age),
which effectively spans both pediatric and adult
criteria. Applying the pediatric recommendations
to this population would result in 6-fold more
patients qualifying for statin therapy than would
be eligible based on the adult guidelines (2.5%
vs. 0.4%, respectively). This equates to approximately 400,000 adolescents.22 This discrepancy
illustrates the challenge faced by providers who
care for adolescents who are transitioning into
adulthood; specifically, whether the risk of exposing significantly more children to chronic lipid381
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Table 2. Risk Factor Definitions for Dyslipidemia Guidelines18
Positive Family History

myocardial infarction, angina, coronary artery bypass graft/stent/angioplasty, sudden
cardiac death in parent, grandparent, aunt, uncle at <55 yr for males, < 65yr for females

High level risk

Hypertension that requires drug therapy (BP ≥ 99th percentile + 5 mm Hg), current
cigarette smoker, BMI at the ≥ 97th percentile, presence of special high-risk conditions

Moderate level risk

Hypertension that does not require drug therapy, BMI ≥ 95th percentile, <97th
percentile, HDL cholesterol < 40 mg/dL, presence of moderate risk conditions

Special high-risk
conditions

Type 1 or 2 diabetes mellitus, chronic kidney disease/end-stage renal disease/posttransplantation, post-orthotopic heart transplantation, Kawasaki disease with current
aneurysms

Special moderate-risk
conditions

Kawasaki disease with regressed coronary aneurysms, chronic inflammatory disease
(systemic lupus erythematosus, juvenile rheumatoid arthritis), HIV infection, nephritic
syndrome

BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; RF, risk factor

lowering medications is offset by the anticipated
reduction in morbidity and mortality from CAD.
The risk of this chronic extrahepatic exposure of
statins in the developing child is described briefly
in Distribution below. Undoubtedly, additional
investigations will be needed to clarify future
guideline updates and risk of statin exposure in
a developing child.

OVERVIEW OF THE STATINS
As shown by the guidelines, HMG-CoA reductase inhibitors are now the mainstay of pharmacologic treatment for dyslipidemia in both adults
and children, due to their demonstrated efficacy
in the primary and secondary prevention of CAD
coupled with a relatively mild side effect profile.15,23-28 The first 3 statins approved in the United
States (lovastatin in 1987, simvastatin in 1991, and
pravastatin in 1991) are fungus-derived (Tables
3-5) semisynthetic agents, whereas the remaining
U.S. Food and Drug Administration-approved
compounds (fluvastatin in 1993, atorvastatin in
1996, rosuvastatin in 2003, and pitavastatin in
2009) are synthetic agents (Table 6).29
Pharmacology
Statins decrease the hepatic synthesis of cholesterol by blocking the conversion of HMG-CoA to
mevalonate, the rate-limiting step in cholesterol
synthesis. In response to a subsequent decrease
in intracellular sterols, expression of the genes
encoding the cell-surface LDL receptor is upregulated. This, in turn, enhances the hepatic
uptake of LDL and reduces the circulating levels
of LDL in the serum.30 However, statins appear
to possess other effects including a decrease
382

in inflammatory mediators downstream from
HMG-CoA reductase (see Future Considerations
below).31-33 Thus, it remains debated whether the
reduction in CAD and plaque formation occurs
as a result of the statins’ lipid-lowering effects or
other anti-inflammatory effects.
Efficacy in Children
Clinical trials of statins in children have included lovastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin, atorvastatin, and pitavastatin
and most of the studies focused on lipid-lowering
and safety (Tables 3-6). With few exceptions, exposure to the statins conferred no added safety
risk compared with placebo. However, the trials
described in Tables 3 to 6 ranged from 1 month
to 2 years and thus, a paucity of data describing
the safety of chronic exposure to statins initiated
during childhood exists. Moreover, for nearly all
agents, reductions in LDL exceeded 20%, and
some agents achieved reductions in excess of 40%
to 50%. There also appeared to be some degree
of dose dependence in LDL response within
this class of drugs. However, in many studies,
the variability associated with mean response
profiles was exceedingly large, almost equivalent
in magnitude to the response itself (Tables 3-6).
At present, the cause of this variability remains
unknown.
With such a high degree of variability in LDL
reduction at a given statin dose and the unknown long-term developmental consequences
of regular pediatric statin use, identifying the
dose that maximizes efficacy and minimizes
the risk of toxicity (i.e., dose optimization) is of
great clinical importance for a developing child.
Notably, all studies presented used a “one-sizeJ Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org
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Table 3. Lovastatin: Summary of Safety and LDL reduction in Pediatric Trials
Reference

Population

Lovastatin
Dosing

LDL reduction Variance
(%)
(%)

Clauss et al34

n = 54;
11-18 yr (females only)
FH

20 mg/day × 4 wks
40 mg/day × 20 wks

Stein et al35

Safety

23 at wk 4
27 at wk 24

SE 3.3
SE 3.4

no difference vs.
placebo

n = 132 (65 placebo);
10 mg/day × 8 wks
13.3 ± 2.5 yr (males only) 20 mg/day × 8 wks
FH
40 mg/day × 8 wks
40 mg/day × 24 wks

17
24
27
25

SE 2
SE 1
SE 2
SE 2

no difference vs.
placebo

10 mg qd × 8 wks
Lambert et al36 n = 69;
13.3 ± 2.7 yr (males only) 20 mg/day × 8 wks
FH
30 mg/day × 8 wks
40 mg/day × 24 wks

21
24
27
36

15 - 27
19 - 29
19 - 35
33 - 39

no SAE,
increase in CK

CK, creatinine kinase; FH, familial hyperlipidemia; SAE, serious adverse events; SE, standard error

fits-all” dosage scheme, effectively ignoring the
contributions of ontogeny and genetic variation
in statin disposition that are assuredly present in
pediatric patients.
Given that the use of statins will inevitably
increase as a result of mandatory lipid screening
programs and the observed difficulties with adherence to dietary/behavioral modifications, the
pediatric community should proactively pursue
a more comprehensive understanding of these
agents in children and adolescents before their
widespread use. The following section discusses
developmental, physicochemical, and pharmacogenetic factors that influence the dose-exposure
profile for the statins. Notably, the paucity of data
for pediatric statin disposition requires extrapolation from in vitro and adult data.

DISPOSITION
Physiochemical Considerations
Despite sharing a common mechanism of action, the statins differ in their physicochemical
properties (e.g., octanol-water partition coefficient, pH stability/solubility). These properties
are incredibly important to the overall disposition of each agent and explain why the statins
should be considered independently when
tailoring dosage to individual patient populations. Two statin agents (lovastatin and simvastatin) are formulated as lactone prodrugs which
require hydrolysis to become activated inhibitors of HMG-CoA reductase.56,57 The remaining
statins are administered in their active hydroxy
acid forms.31,58,59 Consequently, lovastatin and
simvastatin are the most lipophilic as delivered
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org

(simvastatin > lovastatin), readily translocating
across membranes,60,61 whereas pravastatin and
rosuvastatin are the most hydrophilic agents,
requiring transporter-mediated disposition.58,60,61
Another unique element of the statins lies with
the pH-dependent chemical interconversion that
can occur at any step in the disposition pathway
and heavily influences the amount of active drug
available at the target. For instance, formation of
the inactive 3-alpha-hydroxy-pravastatin acid
and lactone isomers in the acidic environment
of the stomach prior to absorption can disrupt
the amount of pravastatin acid delivered to the
drug target (i.e., the liver).62,63 Not surprisingly,
isomer formation influences the pharmacodynamic effects of these drugs and is highly variable
among healthy human subjects.63,64 Although
these data require replication in a larger cohort
before changes can be made to the drug label,
the extent of chemical interconversion should be
taken into consideration in populations where
statin response is highly variable.
Absorption
All statins are administered orally, thus, the
extent of their systemic availability is determined
by the aforementioned physicochemical properties of the drug, the physicochemical milieu of
the patient’s gastrointestinal environment, and
the functional status of their intestinal transporters, which can be influenced by ontogeny and
genetics.
Pravastatin preferentially undergoes transporter-mediated absorption, conferring a relatively
robust absorption rate despite its hydrophilic
properties.65 In vitro, pravastatin appears to be
383
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Table 4. Pravastatin: Summary of Safety and LDL Reduction in Pediatric Trials
Reference

Population

Pravastatin Dosing

% LDL
Reduction

Hedman et al43

n = 20;
4.9-15.6 yr
FH

10 mg/day × 8 wk

21

Hedman et al44

n = 19;
10 mg/day × 8 wk
4.4 - 18.9 yr
cardiac transplant

27

Hedman et al45

n = 35;
4.1 - 18.5 yr
FH
n = 35

Hedman et al46

n = 20;
4.9 - 15.6 yr
FH

% Variance

Safety

Not reported No SAE

SD 27

No SAE, mild
increase in CK

10 mg/day
25 at wk 8
Titration by 10 mg at 8, 16, 27 at wk 16
24, 52, 104 wk per LDL goal 29 at wk 24
33 at wk 52
32 at wk
104

SD 11
SD 13
SD 13
SD 14
SD 13

No SAE

10 mg/day × 8 wk

20 (TT)
23 (TC)

SD 10
SD 12

No SAE

Hedman et al46

n = 12;
10 mg/day × 8 wk
4.4 - 18.7 yr
cardiac transplant

34 (TT)
8 (TC)

SD 21
SD 8

No SAE

Knipscheer et al47

n = 72;
8 - 16 yr
FH

5 mg/day × 12 wk
10 mg/day × 12 wk
20 mg/day × 12 wk

23
24
33

18-28
19-29
29-37

No difference
between
groups

Wiegman et al48

n = 214;
13 ± 3 yr
FH

20 or 40 mg/day (< 14 vs. ≥
14yr) × 104 wk

24

SD 17

No difference
vs. placebo

CK, creatinine kinase; FH, familial hyperlipidemia; LDL, low-density lipoprotein; SAE, serious adverse events; SD, standard deviation; TC,
SLCO1B1 521TC heterozygote genotypes; TT, SLCO1B1 521TT wild-type genotypes.

a substrate for the influx transporters OATP1A2
and OATP2B1. Notably, OATP2B1 uptake appears to be pH-sensitive, diminishing greatly
as the pH increases from 5.0 to 7.4.66-68 This
observation suggests that the primary impact
of OATP2B1 translocation occurs at the level
of the enterocyte, where it is exposed to lower
pH values, as opposed to the hepatocyte, where
the systemic pH is higher and less uptake is
expected. Pravastatin is not a substrate for the
efflux transporters MDR1 and BCRP but, in vitro,
appears to be a substrate for the efflux transporter
MRP2, which is located on the apical surface of
the enterocyte and liver.68-71 In vivo, increased
expression of MRP2 conferred by a ‘gain of function’ sequence variation (ABCC2 c.1446C>G),
increases presystemic clearance and reduces the
bioavailability of pravastatin at the level of the
enterocyte.72
Rosuvastatin similarly undergoes transportermediated absorption and, although not fully
characterized, also appears be a substrate for
384

OATP2B1 and BCRP.73,74 However, rosuvastatin
does not display the same pH sensitivity suggesting that OATP2B1 may be relevant to rosuvastatin disposition at the level of both the intestine
and liver.73 In vivo, a genetic variation in the gene
encoding BCRP (ABCG2 c.421C>A) contributes
to an increase in rosuvastatin exposure by way of
diminished export back into the intestinal lumen
and into the biliary canaliculus.75,76
Fluvastatin, moderately more lipophilic than
pravastatin or rosuvastatin, undergoes passive
diffusion but in vitro is a substrate of OATP2B1.73
Similarly, in vitro data reveal that atorvastatin is
an OATP2B1 substrate at acidic and neutral pH;
however, the high passive diffusion rates that are
observed and lack of disruption in absorption
by known inhibitors of OATP2B1 suggest that
this transporter plays a very minor role in the
absorption of atorvastatin.73 Pitavastatin, also
moderately lipophilic, undergoes passive diffusion and there is no evidence that transportermediated influx significantly influences the
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org

JPPT

Pediatric Statin Administration

Table 5. Simvastatin Summary of Safety and LDL Reduction in Pediatric Trials
Reference

Population

de Jongh et al37

n = 173;
14.4 ± 2.1 yr
FH

10 mg/day × 8 wk
20 mg/day × 8 wk
40 mg/day × 8 wk
40 mg/day × 24 wk

Ferreira et al38

n = 36;
10.3 ± 4 yr
HC

10 mg mg/day × 4 wk

Dirisamer et al39 n = 20;
13 ± 2.4 yr
FH
de Jongh et al40

n = 50;
14.2 ± 3.1 yr
FH

Stefanutti et al41 n = 16;
4 - 12 yr
FH
Garcia-de-laPuente et al42

Simvastatin Dosage

% LDL
Reduction

% Variance

31 at wk 8
35 at wk 16
38 at wk 24
41 at wk 48

SD 11
SD 12
SD 16
SD 39

No SAE,
Slight decrease in
DHEA-S

37

SD 12

No difference vs.
placebo

25 (5 mg)
30 (10 mg)
36 (20 mg)

Not reported

No differences
between groups

10 mg/day × 8 wk
20 mg/day × 8 wk
40 mg/day × 12 wk

40

19%

No differences vs.
placebo

10 mg/day × 52 wk

29

Not reported

No difference vs.
placebo

34

Not reported

No difference vs.
placebo

5 or 10 mg/day (LDL < 220
vs. ≥ 220)
step-wise titration up to
20 mg × 52 wk

n = 25;
5 or 10 mg/day (≤30 vs.
4 - 17 yr
>30 kg) × 4 wk
renal disease 10 mg or 20 mg titration
(at wk 4) × 8 wk

Safety

DHEA-S, dehydroepiandrosterone-sulfate; FH, familial hyperlipidemia; HC, hypercholesterolemia; LDL, low-density lipoprotein; SAE, serious
adverse events; SD, standard deviation.

disposition of this drug. However, pitavastatin
absorption can be attenuated presystemically
by P-glycoprotein (P-gp).77,78 Finally, there is no
reported transporter-mediated absorption influencing the simvastatin or lovastatin lactones.
Another factor for consideration with respect
to the absorption of statins is the impact of coadministered meals. Regardless of whether the drug
is delivered by solution or capsule, concurrent
administration of fluvastatin with food markedly
reduces exposure and delays absorption (area under the curve [AUC], −17% to −24%; Cmax, −60%
to −73%; Tmax, +56%).79 This was also observed
with pravastatin (AUC, −30%; Cmax, −49%; Tmax,
+50%)80 and rosuvastatin (AUC, −93%; Cmax,
−93%; Tmax, +10% ).81 However, meals markedly
slow the rate of absorption for atorvastatin (Tmax,
+124%) and pitavastatin (Tmax, +143%). In fed
states, atorvastatin Cmax (−48%) and pitavastatin
Cmax (−55%) are reduced, although the impact
on the extent of exposure for atorvastatin (AUC,
−13%) and pitavastatin (AUC, −15%) is less
pronounced.82,83 In contrast, lovastatin concentrations drop when administered under fasting
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org

conditions (~33%),84 whereas simvastatin can be
taken without regard to meals.85
A final observation is the differential effect of
morning versus evening dosage for the statin
agents. When pravastatin is given in the evening,
the Cmax and AUC are reduced by approximately
60% compared with those for morning dosage.86
Similarly, the Cmax and AUC of atorvastatin are
reduced by roughly 30% when administered in
the evening.87 Fluvastatin concentrations are reported to be higher following evening dosage,88
while no significant differences were observed
for rosuvastatin.89 These differences in drug exposure relative to the timing of dosage could be
secondary to physiologic patterns of gastric emptying. Circadian changes in drug absorption have
been observed in response to increased gastric
emptying times in the evening.90 Additionally,
the diurnal pattern of cholesterol biosynthesis
(peak, 12:00 midnight to 4:00 am) in relation to
an evening dose could increase amount of statin
used by the hepatocyte and thereby affect the
plasma exposure of a statin.91,92 Whether these
differences definitely arise as a result of changes
385
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Table 6. Synthetic Statins: Summary of Safety and LDL Reduction in Pediatric Trials
Agent (reference)

Population

Dosage

n = 84;
20 mg/day for 6 wk
Fluvastatin
(van der Graaf et al49) 12.6 ± 2.1 yr Titration to 40- or
FH
80-mg intervals per
LDL × 96 wk

% LDL Reduction

% Variance

Safety

34

29 - 39

N/A, no placebo
arm

Atorvastatin
(McCrindle et al50)

n = 187;
14.1 ± 2.0 yr
FH or
severe HC

10 mg/day titration
to 20 mg at wk
4 based on LDL
continuing over
26 wk

40

SE 1

No difference vs.
placebo

Atorvastatin
(Gandelman et al51)

n = 39;
6 to <18 yr
FH

5 or 10 mg/day × 8
wk (< 10 vs ≥ 10yr)
Titration per LDL
at wk 4

37 (5 mg)
43 (5 mg to 10 mg)
38 (10 mg)
41 (10 mg to 20 mg)

SD 11
SD 6
SD 8
SD 12

No difference
between groups

Atorvastatin
(Argent et al52)

n = 18;
13 ± 4
renal
transplant

5 or 10 mg/day (<
40 kg vs. ≥ 40 kg) ×
36 wk

57

SD 7

No difference vs.
untreated

Rosuvastatin
(Avis et al53)

n = 176;
13.8 ± 1.7
FH

5, 10, 20 mg/day
titration at wk 12
per LDL × 40 wk

38
45
50

SD 13
SD 17
SD 14

No difference vs.
placebo

Rosuvastatin
(Marais et al54)

n = 44;
8 - 63 yr
hoFH

20 mg/day × 6 wk
40 mg/day × 6 wk
80 mg/day × 6 wk

19
23
21.4

SD 16
SD 15
SD 21

No SAE

Pitavastatin
(Braamskamp et al55)

n = 106;
6 - 17 yr
FH

1 mg/day × 12 wk
2 mg/day × 12wk
4 mg/day × 12wk

23.5
30.1
39.3

SE 2.1
SE 2.1
SE 2.2

DHEA-S
significantly
decreased (4 mg
group)

DHEA-S, dehydroepiandrosterone-sulfate; FH, familial hyperlipidemia; HC, hypercholesterolemia; hoFH, homozygous familial hyperlipidemia; LDL, low-density lipoprotein; SAE, serious adverse events; SD, standard deviation; SE, standard error.

in absorption, distribution or elimination or intrinsic cholesterol production patterns remains
unclear; however the observation that these
patterns do not appreciably alter lipid-lowering
properties of the affected statins limits the clinical
relevance of these findings.
Concurrent with and subsequent to oral
absorption, the statins (with the exception of
pitavastatin) are subject to extensive first-pass
extraction, effectively reducing their bioavailability.29,59,93-96 Because drug-metabolizing enzymes
mediate statin metabolism, these reactions are
reviewed in Metabolism below. However, we
point out here that when first-pass occurs at the
level of the intestinal enterocyte, the absolute
bioavailability of these agents is reduced, influencing both efficacy and toxicity. In contrast,
when hepatocytes are the principal mediators of
first pass, a more favorable scenario is set where
concentrations at the target organ (i.e., the liver)
386

increase while peripheral exposure decreases,
thereby leading to enhanced efficacy and fewer
side effects (e.g., myalgias).97
Distribution
Hepatic uptake for the highly lipophilic statin
lactones occurs by passive diffusion,60 but for
most of the statins, it is facilitated by transportermediated processes. OATP1B1, encoded by the
solute-carrier organic anion transporter gene
SLCO1B1, is the principle transporting protein
into the hepatocyte for most statins and has
been reviewed extensively.60,98-100 Among the
transporters with a minor role in statin disposition, pitavastatin, rosuvastatin, and fluvastatin
are substrates for OATP1B3 (SLCO1B3),60,101,102
rosuvastatin and fluvastatin appear to be substrates for OATP2B1 (SLCO2B1),73,103,104 and rosuvastatin also appears to be a substrate for the
sodium-dependent cotransporting polypeptide
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org
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(NTCP) which may account for as much as 35%
of its hepatic uptake.103 Fluvastatin also appears
to enter the hepatocyte by passive diffusion.105-107
As above, cellular uptake of the simvastatin and
lovastatin lactones relies primarily on passive
diffusion; however, simvastatin and lovastatin
acid are substrates of OATP1B1 in vitro and in
vivo.108,109 Notably, the simvastatin and lovastatin
lactones appear to inhibit OATP1B1-mediated
transport.110,111
The clinical relevance of OATP-mediated statin
disposition has been demonstrated in a number
of drug-drug interaction studies. A 7-fold increase
in the AUCs of atorvastatin acid and 2-hydroxy
atorvastatin acid and a 3-fold increase in AUC of
4-hydroxy atorvastatin acid were observed when
this statin was coadministered with rifampin (a
known inhibitor of OATP1B1 and OATP1B3).112-114
In the presence of cyclosporine (a potent inhibitor
of OATP1B1 and CYP3A4) atorvastatin AUCs
were 6- to 15-fold increased,115-117 fluvastatin
AUC was 3-fold increased,118 lovastatin AUC
was 20-fold increased,119 pitavastatin AUC was
5-fold increased,99 pravastatin AUC was 5- to
10-fold increased,44,119,120 rosuvastatin AUC was
7-fold increased,121 and simvastatin AUC was
3- to 8-fold increased.122,123 Certainly, CYP3A4
inhibition from cyclosporine can contribute to
the overall increases observed in statin exposure;
however, this can be concluded to play a minor
role given that rosuvastatin, pravastatin, and
pitavastatin are not significantly metabolized
by CYP3A4.124-128 In fact, pravastatin, the most
hydrophilic compound, had a 10-fold increase
in AUC when administered to children and
adolescents who were taking triple immunosuppressive therapy containing cyclosporine and
no other CYP substrates.44 Gemfibrozil, also an
inhibitor of OATP1B1 and CYP2C8, produced a
2-fold increase in AUCs of atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and
simvastatin.99,129-133
Cumulatively, the data from the abovedescribed studies provide compelling evidence
that OATP1B1 is a critically important determinant of drug disposition for most of the statins.
Consequently, functional polymorphisms in the
SLCO gene families are also expected to influence statin disposition and, thus, have been
the subject of considerable interest.99,134 Much
of this work stems from a study of pravastatin
pharmacokinetics, where extreme outliers were
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attributed to 2 single-nucleotide variants in
SLCO1B1.135 These mutations were observed in
the promoter region ( −11187G>A) and in exon
5 (c.521T>C) and were associated with a 50%
reduction in non-renal clearance.136 This finding
was independently confirmed in heterozygous
carriers of SLCO1B1*15 (containing the 388A>G
and 521T>C variants) who demonstrated mean
pravastatin exposures (AUC 0–12) that were 93%
higher and heterozygous carriers of the *17 haplotype (containing the −11187G>A, 388A>G, and
521T>C variants) who had exposures that were
130% higher than non-carriers.137
Ultimately, the functional consequence of
SLCO1B1 sequence variations on statin exposure
are reflected by the dependence of the individual
statin on OATP1B1 for cellular uptake. Heterozygosity for SLCO1B1*5 and *15 haplotypes is associated with a 3-fold, 2.5-fold, and 2-fold increase
in exposure for simvastatin acid, atorvastatin and
pravastatin, respectively, with very little effect on
fluvastatin.99 SLCO1B1 genotype also influences
the effect of rifampin on atorvastatin exposure
wherein a 9-fold increase in AUC is observed in
patients with a fully functional 521TT genotype
versus a 5-fold increase in AUC observed for the
521CC genotype.138 We would be remiss not to
allude to the in vitro data which suggest that the
C800T variant of NTCP may confer enhanced
uptake of rosuvastatin, but there are no clinical
data to support a role for this mutation in vivo.103
These studies underscore the critical role of
OATP1B1 in statin disposition. By extension, this
has important implications for drug safety, where
an increase in systemic exposure mediated by
reduced OATP1B1 activity can increase the risk
of myopathy in statin-treated patients. The Statin
Response Examined by Genetic Haplotype Markers (STRENGTH) trial demonstrated this with the
observation that patients who were heterozygous
for a non-coding sequence variation in linkage
disequilibrium with c.521T>C experienced a 4.5fold increase in risk of myopathy. Patients who
were homozygous for this mutation experienced
a 16.9 increase in risk of myopathy.139
All statins, except for pravastatin, are extensively protein bound. 56,57,65,95,96,125,140,141 Therefore,
the circulating concentration of free drug is relatively low for most agents in this class. However,
the extent of distribution into peripheral tissues
in humans is not well characterized. In theory,
the statins with reduced lipid solubility (e.g.,
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pravastatin) should demonstrate less extensive
tissue distribution, which would ostensibly provide a safer alternative in children, where brain
and gonadal tissues are still maturing. In vitro
and in vivo data support this supposition, demonstrating that lower exposures are observed for
pravastatin than for lovastatin and simvastatin in
the central nervous system,142,143 and pravastatin
also manifests a lower risk of myopathy than
simvastatin and atorvastatin do.144-149 However,
there are contradictory data which suggest that
pravastatin can influence gene expression in
the central nervous system to the same extent
as some of the other statins.143 Until the active
transporters responsible for tissue distribution
of the statins and their ontogeny in children are
more fully elucidated, practitioners will need to
rely on the adverse event profiles reported from
clinical studies.
Metabolism
Although in vitro reaction phenotyping studies
suggest that cytochromes P450 (CYP) 2C8, 2C9,
2C19, 2D6, 3A4, and 3A5 are all capable of metabolizing the statins, current data suggest that
CYP3A4 is a major contributor to simvastatin,
lovastatin, and atorvastatin metabolism.95,150-152
In the presence of the CYP3A4/5 inhibitor troleandomycin, simvastatin acid metabolism is
decreased by 90%.150 When administered concurrently with the CYP3A4 inhibitor itraconazole,
15- to 19-fold increases are observed in simvastatin and lovastatin AUCs.98,126-128 The impact
of itraconazole on the AUC of atorvastatin is
more modest (+47%),151 and the coadministration of CYP3A4 inhibitors has no significant
effect on clearance of pravastatin, fluvastatin,
rosuvastatin, or pitavastatin, consistent with the
limited role of CYP3A4 in the metabolism of these
compounds.153 In vitro and in vivo data suggest
that fluvastatin is a substrate for CYP2C9,154-156
whereas pravastatin, pitavastatin, and rosuvastatin do not undergo appreciable CYP-mediated
metabolism.
Despite the fact that CYP3A4 activity is highly
variable, mutations driving this variability have
not been fully elucidated.157 However, a sequence
variation in intron 6 of this gene associated
with reduced CYP3A4 expression and activity
(rs35599367 C>T, designated CYP3A4*22) has
also been associated with the need for 0.2- to
0.6-fold lower doses of atorvastatin, lovastatin,
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and simvastatin to adequately manage lipid profiles.158,159 With fluvastatin, patients homozygous
for the *3 allele of CYP2C9 (which confers reduced activity in this enzyme) demonstrate 3-fold
lower clearance values of the active fluvastatin
enantiomer. Notably, the resultant lipid profiles
were not correlated with CYP2C9 genotype.160
Collectively, these studies support a role for allelic variations in drug-metabolizing enzymes
influencing the pharmacokinetics and, in some
cases, pharmacodynamics of the statins that rely
on these pathways for clearance.
UDP-glucuronosyl transferase (UGT)-catalyzed conjugation is the primary route by which
statins and their metabolites are further biotransformed in hepatocytes.161,162 The open acids are
conjugated by UGT to form an acyl glucuronide
that subsequently cyclizes to form a lactone ring
(i.e., lactonization). This process results in a loss
of pharmacologic activity and is common to all
statins present in the open acid form. Notably,
carboxyl esterase can reverse the lactonization
process thereby regenerating the open acids.
Alternatively, the lactones can be directly metabolized by the CYPs in a process that appears
to occur more rapidly than is observed for open
acids.60,163 Although important in the disposition
of statins, the overall contribution of UGTs is
quantitatively less substantial than that of the
CYPs.163 As above, pravastatin, rosuvastatin,
and pitavastatin do not undergo extensive UGTmediated conjugation.
Although conjugation plays a more limited
role in statin disposition, recent data suggest
that allelic variants of UGT may have a modest
effect of statin activity. The UGT1A3*2 allele
has been associated with increased lactonization activity for atorvastatin.164 Homozygosity
of the UGT1A3*2 allele was accompanied by a
1.7- and 2.7-fold increase in AUC of the parent
and 2-hydroxyatorvastatin lactones, respectively,
compared to that in patients who are homozygous for UGT1A3*1. Furthermore, this increase
in lactone formation correlated with a reduction
in the maximal effect of atorvastatin on total and
LDL cholesterol-lowering from baseline.165
Excretion
Biliary excretion of the UGT-conjugated statins
occurs through several transporters, including
multidrug resistance 1 (MDR1; ABCB1), multidrug resistance-associated protein 2 (MRP2;
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org
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ABCC2), breast cancer resistance protein (BCRP;
ABCG2), and bile salt exporting pump (BSEP;
ABCB11). However, the quantitative importance
of these efflux transporters in the overall disposition profile of the statins has yet to be fully elucidated. Nonetheless, the consequences of genetic
variations in the efflux transporters relevant to
the statins have also recently been examined.
In vitro, there is no consensus regarding MDR1
expression or activity in the common allelic
variants of ABCB1 (c.1236C>T, c.2677G>T/A,
c.3435C>T).166 In vivo, these allelic variants do
not appear to significantly influence the interindividual variability in fluvastatin, pravastatin,
lovastatin, and rosuvastatin pharmacokinetics,167
but significantly increase the exposure of simvastatin and atorvastatin acid by 60% and 55%,
respectively.168
Conversely, the ABCG2 c.421C>A variant,
which has been associated with transport activity in vitro,169 appears to increase the exposure
of atorvastatin, fluvastatin, simvastatin lactone,
and rosuvastatin by 72%, 72%, 111%, and 144%,
respectively, in subjects with the AA genotype
compared to those in patients with the wild-type
CC genotype.75,170 Note that this genotype does
not appreciably impact the pharmacokinetics of
simvastatin acid or pravastatin.170 As discussed
in Absorption above, pravastatin is subject to
MRP2-mediated transport in vitro at the level
of the enterocyte and hepatocyte.69-71 In vivo, the
ABCC2 c.1446C>G variant decreases the exposure of pravastatin (AUC, −68%) compared to
wild-type controls secondary to a “gain of function” mutation.72 It remains unknown whether
this decrease in exposure is due to enhanced presystemic and/or hepatic clearance. Conversely,
Mrp2-deficient rats have significantly diminished
biliary clearance of pravastatin,71 and in vitro
data suggest that BSEP may be an alternative
mechanism by which pravastatin is cleared from
the hepatocyte.171
Renal clearance is far less pronounced than
biliary excretion. Most of the statin agents
have minimal renal clearance (< 10%) after an
orally administered dose,56,57,59,79,124,172 except for
pravastatin in which 20% is renally cleared.62 The
exposure of pravastatin acid is not impacted by
diminished renal function; however, exposure of
the 3-alpha-hydroxy-pravastatin metabolite was
significantly increased (AUC, +48%) compared
to that in subjects with normal renal function.173
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org
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Halstenson et al173 suggest that this increased
interconversion occurs secondary to decreased
gastric pH, which is a direct result of kidneyrelated metabolic changes. Hepatic conversion
to 3-alpha-5-beta, 6-beta-trihydroxy isomeric
metabolite occurs more frequently in severe renal
impairment, suggesting that more pravastatin
acid is cleared hepatically. Although renal impairment does not appear to alter the exposure
of pravastatin acid, the impact of both metabolites on statin disposition and response require
further investigation. In vitro, pravastatin is a
substrate of organic anion transporter 3 (OAT3),
a transporter located on basolateral membrane
of the proximal tubule, and it is responsible for
its uptake in the kidney.174,175 In vitro, gemfibrozil
inhibits pravastatin uptake in OAT3-expressing
cells.176 In vivo, coadministration of pravastatin
and gemfibrozil lead to an increase in pravastatin
exposure (AUC, +202%) and decreased renal
clearance (−40%).131 This 40% reduction in renal
clearance does not solely explain the increase
in pravastatin exposure, but it could serve as a
contribution to pravastatin disposition. Further
investigation by Nishizato et al136 found that
several OAT3 single-nucleotide polymorphisms
did not affect pravastatin pharmacokinetics.136
However, the single-nucleotide polymorphisms
included in this analysis have not been associated
with decreased transporter function. Overall,
patients with renal impairment do not require
dose adjustments, but the impact of renal clearance with pravastatin administration requires
further elucidation.
Given the current state of our knowledge
of the disposition pathways for the available
statins (most of which mature prior to adolescence) and the relative absence of data on the
ontogeny of transporter expression which could
influence recommendations for statin dosage
in children, considerations for the selection of
statin agents in the pediatric population will
largely reflect the same considerations used with
adult patients. To maximize the dose-exposure
profile, considerations include whether the
patient is receiving gastric acid-modifying
therapy and whether greater adherence is anticipated to a regimen that requires medication
administration with or without meals. To influence the exposure-response profile, one should
consider the genetic constitution of the patient,
the concurrent administration of drugs that
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Table 7. Statin Studies Under Non-Hyperlipidemic Conditions
Condition
Autoimmune myocarditis

181,182

Investigated Mechanism(s)
Inhibit expression of inflammatory cytokines
Reduce infiltration of T cells
Improve myocardial repolarization

Cardiac allograft vasculopathy183-190

Improve prognosis post-transplant
Reduce expression of cell adhesion molecules
Reduce graft rejection
Reduce circulating monocytes
Improve survival

Cancer191-195

Stimulate antiproliferation
Promote apoptosis
Inhibit angiogenesis
Inhibit cell migration

Chronic kidney disease196-198

Decrease decline in GFR
Prevent contrast induced acute kidney injury
Decrease risk of stroke

Fracture injuries, bone healing, & osteoporosis199-204 Promote mesenchymal cell differentiation to osteoblasts
Protect osteoblasts from apoptosis
Reduce osteoclast activity and bone resorption
HIV205-211

Slow progression of vascular disease on ART
Improve flow-mediated vasodilation
Implement immunomodulation
Reduce all-cause mortality

Immunomodulation212-214

Inhibit interferon production
Decrease T cell activation

Infection215-218

Reduce risk of mortality from bacterial and viral infection

Lupus

Reduce C-reactive protein
Reduce circulating chemokines
Improve endothelial function

Polycystic ovary syndrome223-225

Reduce markers of inflammation
Reduce androgenic steroid concentrations

Rheumatoid arthritis226-231

Reduce risk of mortality
Reduce joint pain/swelling
Reduce markers of inflammation

Rotator cuff injury232,233

Stimulate migration and adhesion of tenocytes
Protect against hyperlipidemia-associated RC injury

Sickle cell disease178,234-236

Reduce thrombin generation/lower circulating procoagulants
Improve endothelial dysfunction

219-222

ART, antiretroviral therapy; GFR, glomerular filtration rate; HIV, human immunodeficiency virus; RC, rotator cuff

compete as substrates for transport pathways,
and comorbidities that may alter circulating
protein stores of the presence of protein-binding
displacers in the circulation. Future studies on
the pharmacokinetics of statins in the pediatric
population, and an expansion of our knowledge
on the developmental patterns of transport
expression, will permit clinicians to further individualize the selection and dosage of statins
in this population.
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FUTURE CONSIDERATIONS
Owing to their pleiotropic effects, the statins
have been extensively evaluated for nonhyperlipidemic conditions, a few of which are
detailed in Table 7, and many of which can impact
children. For example, patients with sickle cell
disease can develop oxidative stress and chronic
inflammation to their distal vasculature as a result of transient vaso-occlusion and subsequent
J Pediatr Pharmacol Ther 2016 Vol. 21 No. 5 • www.jppt.org

JPPT

Pediatric Statin Administration

reperfusion injury.177 Hoppe et al178 found that
biomarkers of vascular dysfunction, including
C-reactive protein and interleukin 6, were decreased in adolescents with sickle cell disease
from 50% to 70% after a 3-week trial of low (20
mg) or moderate (40 mg) doses of simvastatin.
Additionally, statins have been used after
cardiac transplantation to prevent coronary allograft vasculopathy (CAV). In pediatric cardiac
transplantation, the prevalence of CAV has been
reported to be as high as 17% in one retrospective
analysis.179 Greater-than-optimal LDL concentrations (>100 mg/dL) post transplantation have
been reported in 39% of pediatric patients 1 year
after transplantation,180 which can be secondary
to post-transplantation steroid and immunosuppressive therapy. The addition of pravastatin
therapy in pediatric cardiac transplant recipients
yielded a lower incidence of CAV.179
Most of the remaining conditions for which
statins have been explored exploit the anti-inflammatory and antiproliferative effects of these
drugs (Table 7). Thus, it would not be unexpected
to see statin coadministration in the presence of
infections, fractures, and malignancies in children. However, it should be appreciated that
there are an equally large number of publications that refute a role for statins in these same
conditions (Table 7). In the absence of sufficient
prospective clinical trials to inform the role of
these agents for indications other than hyperlipidemia, the practitioner must carefully weigh the
risk-benefit ratio of these agents and thoughtfully
examine the in vitro concentration-effect profiles
to inform whether and at what dose these agents
should be used in pediatric patients.

CONCLUSIONS
With precursors of CAD appearing in childhood, the establishment of pediatric preventive
cardiology services is rapidly emerging. However, the most appropriate management of those
children and adolescents, where lifestyle changes
fail, remains challenging. Despite the overall success of statins, variability in drug response in the
pediatric cohort remains concerning. Although
not discussed above, genes involved with drug
response may contribute to some of the variability in LDL reduction among children and
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adults receiving statin therapy.237-241 However,
it remains unknown whether a consistent statin
concentration (i.e., exposure) at the drug target
was achieved in these studies. Therefore, future
investigations must be designed to characterize
these dose-exposure relationships in the developing child so that exposure can be controlled
when attempting to determine response in this
population. Once the covariates that influence
statin disposition in children are validated,
future clinical trials will be better informed to
fully characterize the entire dose-exposureresponse relationship. With these data, dosage
will be optimized to maximize efficacy while
minimizing toxicity in the individual pediatric
patient. In the interim, understanding the statin
disposition pathway will assist pediatric providers who make recommendations related to statin
prescribing where alteration of drug delivery and
dosage may be appropriately tailored to meet
their specific patient needs.
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